Heart drug digoxin tested for alcoholic hepatitis – early trial halted

NCT ID NCT05014087

Terminated Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small, early-phase study tested whether the heart medication digoxin could reduce inflammation in people with severe alcohol-associated hepatitis. 23 participants were randomly assigned to receive intravenous digoxin or no digoxin for up to 28 days. The trial was terminated early, so the results are limited and should be interpreted with caution.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: digoxin (intravenous)
What this could lead to: If it works, this could point toward a new way to reduce liver inflammation in people with severe alcohol-related hepatitis.
What could go wrong: This was a very small, early-phase trial that was terminated early, so results are limited. Digoxin is a heart medication and can have serious side effects, especially in people with liver or kidney problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ALCOHOLIC HEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol-induced disorders alcoholic fatty liver disease alcoholic hepatitis drug-induced liver injury hepatitis liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ALCOHOLIC HEPATITIS ALCOHOL-INDUCED DISORDERS CHEMICAL AND DRUG INDUCED LIVER INJURY STEATOHEPATITIS CAUSED BY INGESTIBLE ALCOHOL

Contacts and locations

Locations

Yale New Haven Hospital, Yale School of Medicine

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.